Side-by-side · Research reference

BPC-157vsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED9/53 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

BPC-157

Teriparatide

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011 Sikiric 2018

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

No known endogenous receptor; mechanism still under investigation

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Teriparatide

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily

Intermittent administration preserves anabolic effect.

Lower / starter dose

200 mcg / day

Conservative starter for new users.

—

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

RCT / FDA-approved

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

—

Reconstitution

Bacteriostatic water, 1–2 mL

—

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Morning or evening (flexible)

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

—

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Route

—

Subcutaneous (thigh or abdomen)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

BPC-157

Teriparatide

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

BPC-157

Teriparatide

Injection site reaction

Mild irritation (anecdotal)

Erythema, bruising, pain (uncommon)

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

BPC-157

Teriparatide

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Teriparatide

— no documented stacks